Taylor Wessing LLP has a strong niche practice advising on venture capital investments into spin-outs, early-stage and multinational companies, many of which are based around Cambridge. Its focus on life sciences and technology sees it frequently involved in the commercialisation of innovative products. Practice head Ross McNaughton, who focuses on the biotech, medical devices and diagnostics sectors, and senior associate Oli Denne 'have solid commercial acumen and an ability to distil the negotiation dynamics into clear recommendations'. IP specialist Adrian Toutoungi also has a central role in the practice.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘Top-tier venture capital practice that is our preferred choice for any UK deal. The team has great knowledge of the latest trends and market practices, while being pragmatic and not shy to recommend a way forward, which ensures a high degree of deal certainty.’
‘Ross McNaughton and Oli Denne. They both have solid commercial acumen and an ability to distil the negotiation dynamics into clear recommendations of how to quickly find a way forward. While having our best interest in mind, they are great at project managing transactions, keeping stakeholders informed and aligned - also when representing a syndicate of multiple investors.’
‘Extremely deep knowledge about the international biotech space. Experts in both licensing, fund raising and M&A. Pragmatic, realistic, and bridge builders. Particularly strong with academic and university led spin outs and managing expectations and inexperience that lead to a fair consensus.’
Key clients
- Apollo Therapeutics
- Nuclera
- CamenaBio
- Tagomics
- Infinitopes
- Alveogene
- 2150
- Lingotto
- Multiomic Health
- CodingBio
- Neobe
- Bitrobius Genetics
- Baseimmune
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
The lawyer(s) leading their teams.
Ross McNaughton